YTH domain-containing family protein 1 (DF1) (Dermatomyositis associated with cancer putative autoantigen 1) (DACA-1)
1_MSATS 6_ VDTQR 11_ TKGQD 16_ NKVQN 21_ GSLHQ 26_ KDTVH 31_ DNDFE 36_ PYLTG 41_ QSNQS 46_ NSYPS 51_ MSDPY 56_ LSSYY 61_ PPSIG 66_ FPYSL 71_ NEAPW 76_ STAGD 81_ PPIPY 86_ LTTYG 91_ QLSNG 96_ DHHFM 101_ HDAVF 106_ GQPGG 111_ LGNNI 116_ YQHRF 121_ NFFPE 126_ NPAFS 131_ AWGTS 136_ GSQGQ 141_ QTQSS 146_ AYGSS 151_ YTYPP 156_ SSLGG 161_ TVVDG 166_ QPGFH 171_ SDTLS 176_ KAPGM 181_ NSLEQ 186_ GMVGL 191_ KIGDV 196_ SSSAV 201_ KTVGS 206_ VVSSV 211_ ALTGV 216_ LSGNG 221_ GTNVN 226_ MPVSK 231_ PTSWA 236_ AIASK 241_ PAKPQ 246_ PKMKT 251_ KSGPV 256_ MGGGL 261_ PPPPI 266_ KHNMD 271_ IGTWD 276_ NKGPV 281_ PKAPV 286_ PQQAP 291_ SPQAA 296_ PQPQQ 301_ VAQPL 306_ PAQPP 311_ ALAQP 316_ QYQSP 321_ QQPPQ 326_ TRWVA 331_ PRNRN 336_ AAFGQ 341_ SGGAG 346_ SDSNS 351_ PGNVQ 356_ PNSAP 361_ SVESH 366_ PVLEK 371_ LKAAH 376_ SYNPK 381_ EFEWN 386_ LKSGR 391_ VFIIK 396_ SYSED 401_ DIHRS 406_ IKYSI 411_ WCSTE 416_ HGNKR 421_ LDSAF 426_ RCMSS 431_ KGPVY 436_ LLFSV 441_ NGSGH 446_ FCGVA 451_ EMKSP 456_ VDYGT 461_ SAGVW 466_ SQDKW 471_ KGKFD 476_ VQWIF 481_ VKDVP 486_ NNQLR 491_ HIRLE 496_ NNDNK 501_ PVTNS 506_ RDTQE 511_ VPLEK 516_ AKQVL 521_ KIISS 526_ YKHTT 531_ SIFDD 536_ FAHYE 541_ KRQEE 546_ EEVVR 551_KERQS
1: Specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, and regulates their stability (PubMed:24284625, PubMed:26318451, PubMed:32492408, PubMed:39900921). M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing (PubMed:24284625, PubMed:32492408). Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex (PubMed:32492408). The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) shares m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation (PubMed:28106072, PubMed:32492408). Required to facilitate learning and memory formation in the hippocampus by binding to m6A-containing neuronal mRNAs (By similarity). Acts as a regulator of axon guidance by binding to m6A-containing ROBO3 transcripts (By similarity). Acts as a negative regulator of antigen cross-presentation in myeloid dendritic cells (By similarity). In the context of tumorigenesis, negative regulation of antigen cross-presentation limits the anti-tumor response by reducing efficiency of tumor-antigen cross-presentation (By similarity). Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation (PubMed:31292544, PubMed:31388144, PubMed:32451507). The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules (PubMed:31292544)